GlassScriptPhysician profile
Ronald D Lee
NPI 1023091667
$6,698.18
in general payments reported to CMS, 2019-2025
45 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $882 · 2021: $1,726 · 2022: $1,305 · 2023: $739 · 2024: $1,004 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.54 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $692.78 | 2019-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $653.52 | 2019-2024 | Provenge |
| Antares Pharma, INC. | $630.90 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $627.24 | 2019-2025 | |
| Astellas Pharma US INC | $438.23 | 2019-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $433.25 | 2020-2024 | Keytruda, Lynparza, Welireg |
| Myovant Sciences INC. | $415.51 | 2021-2022 | |
| Blue Earth Diagnostics | $328.17 | 2019-2024 | |
| Pfizer INC. | $304.04 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $256.51 | 2020-2021 | |
| Boston Scientific Corporation | $168.30 | 2021-2024 | Rezum Generator |
| Tolmar Pharmaceuticals, INC. | $139.03 | 2019-2022 | |
| Rochester Medical Corporation | $138.82 | 2021-2022 | |
| Coloplast Corp | $137.87 | 2019-2024 | |
| Procept Biorobotics Corporation | $100.37 | 2022 |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.